胡文辉，男，博士生导师，广东省“珠江学者”特聘教授，药物化学学科带头人，广州蛇毒与生物毒素研究所所长，兼广州医科大学药学院学术委员会主任，广东省分子靶标与临床药理重点实验室副主任，呼吸病国家重点实验室研究员。

胡教授于2002年毕业于中国协和医科大学药物研究所，开展抗炎药物的研究，获得博士学位。2002年-2006年在美国西北大学医学院从事博士后研究，开展神经退行性疾病的药物研究。2006年-2016年在中国科学院广州生物医药与健康研究院任研究员、新药开发室主任。

立足于尚无有效药物的重大疾病，胡文辉课题开展创新药物的研究，建立了国内具有特色和优势的新药研发团队。在历时20多年的新药研究中,胡教授团队已确立多个全新结构的候选药物。其中，基于神经胶质细胞功能障碍的抗阿尔茨海默氏症新药AD16（哌哒甲酮），已获得国家食品药品监督管理局颁发的1.1类药物临床试验批件，并于2021年11月顺利完成了I期临床试验，化合物专利涵盖了中国、美国、英国、德国、日本等全球多个国家。截至目前，胡教授作为通讯作者已在国际著名学术期刊发表了30多篇研究论文，作为第一发明人获得授权专利30多项。兼任药学学报的编委、广东省药学会药物化学专业委员会副主委、广东省药理学会药物毒理学学会副主委。

联系邮箱：huwenhui@gzhmu.edu.cn

研究方向：创新药物研究

主要科研项目;炎症贯穿于重大疾病的发生、发展过程，通过炎性通路的调控可以改变疾病的进程。胡教授团队通过免疫、抗炎的新药研发管线，针对神经系统、呼吸系统开展脑病、肺炎、肺纤维化等疾病的新药研发。截至目前，胡教授已主持国家科技部、国家自然科学基金委、广东省科技厅的新药重大专项等各类新药基金近20项，金额逾2000多万元。

所获荣誉和奖励:2011年获得广东省优秀共产党员，2014年获得广东省优秀专利奖， 2018年获“珠江学者”特聘教授，2020年获广东省科技进步一等奖（第二负责人）。

主要论文及著作（代表性）

1. Xinyi Wu, Ping Sun, Xiuhui Chen, Lei Hua, Haowei Cai, Zhuorong Liu, Cheng Zhang, Shuli Liang, Yanhong Chen, Dan Wu, Yitao Ou, Wenhui Hu*, and Zhongjin Yang*. Discovery of a novel oral proteasome inhibitor to block NLRP3 inflammasome activation with anti-inflammation activity. Journal of Medicinal Chemistry. 2022 Sep 22, 65(18):11985-12001.  

2. Yanhong Chen#, Xiuhui Chen#, Shuli Liang, Yitao Ou, Geng Lin, Lei Hua, Xinyi Wu, Yinghua Zhou, Zhuorong Liu, Haowei Cai, Zhongjin Yang, Wenhui Hu*, and Ping Sun*. Chlorquinaldol inhibits the activation of nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing protein 3 inflammasome and ameliorates imiquimod-induced psoriasis-like dermatitis in mice. Chemico-Biological Interactions, 2022, 365:110122.

3. Shuli Liang, Zhongjin Yang, Lei Hua, Yanhong Chen, Yinghua Zhou, Yitao Ou, Xiuhui Chen, Hu Yue, Xiangyu Yang, Xinyi Wu, Wenhui Hu*, and Ping Sun*. Ciclopirox inhibits NLRP3 inflammasome activation via protecting mitochondria and ameliorates imiquimod-induced psoriatic inflammation in mice. European Journal of Pharmacology, 2022, 930:175156.

4. Ying Hao, Yitao Ou, Cheng Zhang, Hao Chen, Hu Yue, Zhongjin Yang, Xiaofen Zhong, Wenhui Hu*, and Ping Sun*. Seratrodast, a thromboxane A2 receptor antagonist, inhibits neuronal ferroptosis by promoting GPX4 expression and suppressing JNK phosphorylation. Brain Research. 2022, 148073.

5. Cheng Zhang, Hu Yue, Ping Sun, Lei Hua, Shuli Liang, Yitao Ou, Dan Wu, Xinyi Wu, Hao Chen, Ying Hao, Wenhui Hu*, and Zhongjin Yang*. Discovery of chalcone analogues as novel NLRP3 inflammasome inhibitors with potent anti-inflammation activities. European Journal of Medicinal Chemistry, 2021, 219: 113417.

6. Hao Chen, Xiuhui Chen, Ping Sun, Dan Wu, Hu Yue, Jintao Pan, Xinxuan Li, Cheng Zhang, Xinyi Wu, Lei Hua, Wenhui Hu*, and Zhongjin Yang*. Discovery of dronedarone and its analogues as NLRP3 inflammasome inhibitors with potent anti-inflammation activity. Bioorganic Medicinal Chemistry letter. 2021 Aug 15; 46:128160.

7. Hu Yue, Zhongjin Yang, Yitao Ou, Shuli Liang, Wenmin Deng, Hao Chen, Cheng Zhang, Lei Hua, Wenhui Hu*, Ping Sun*. Tanshinones inhibit NLRP3 inflammasome activation by alleviating mitochondrial damage to protect against septic and gouty inflammation. International Immunopharmacology. 2021, 97, 107819.

8. Ping Sun, Hu Yue, Wenming Deng, Yitao Ou, Guangjin Pan, Xiaofen Zhong*, Wenhui Hu*. Compound AD16 reduces amyloid plaque deposition and modifies microglia in a transgenic mouse model of Alzheimer's disease. ACS Pharmacology & Translational Science. 2021, 3, 6, 1100-1110.

9. Jianghong Dong, Mengjie Xiao, Qinge Ma, Guicheng Zhang, Weijie Zhao,  Mengjie Kong, Yue Zhang, Luyun Qia, Wenhui Hu*. Design and synthesis of pinane oxime derivatives as novel anti-influenza agents. Bioorganic Chemistry. 2020, 102, 104106-104106.

10. Nannan Wu, Guangyu Lian, Jingyi Sheng, Dan Wu, Huiyao Lan, Wenhui Hu*, Zhongjin Yang*. Discovery of a Novel Selective Water-Soluble SMAD3 Inhibitor as an Antitumor Agent. Bioorganic Medicinal Chemistry letter. 2020, 30 (17), 127396.

11. Yitao Ou, Ping Sun, NanNan Wu, Hao Chen, Wenhui Hu*, Zhongjin Yang*. Synthesis and biological evaluation of parthenolide derivatives as potential inhibitors of the NLRP3 inflammasome. Bioorganic Medicinal Chemistry letter. 2020, 30 (17), 127399.

12. Ping Sun, Wei Zhou, Hu Yue, Cheng Zhang, Yitao Ou, Zhongjin Yang*, Wenhui Hu*. Compound AD110 Acts as Therapeutic Management for Alzheimer’s Disease and Stroke in Mouse and Rat Models.  ACS Chemical Neuroscience, 2020, 11 (6), 929-938.

13. Wenmin Deng , Zhongjin Yang, Hu Yue, Yitao Ou, Wenhui Hu*, Ping Sun*. Disulfiram suppresses NLRP3 inflammasome activation to treat peritoneal and gouty inflammation. Free Radical Biology and Medicine, 2020, 152, 8-17.

14. Xin Zhao, Runfeng Li, Yang Zhou, Mengjie Xiao, Chunlong Ma, Zhongjin Yang, Shaogao Zeng, Qiuling Du, Chunguang Yang, Haiming Jiang, Yanmei Hu, Ping Sun, Jianghong Dong, Wei Cui, Kefeng Wang, Jun Wang, Yaoquan Tu, Zifeng Yang, Wenhui Hu*. Discovery of Highly Potent Pinanamine-Based Inhibitors Against Amantadine- and Oseltamivir-resistant Influenza A Viruses. Journal of Medicinal Chemistry. 2018, 61, 5187−5198.

15. Hui Xie, Shaogao Zeng, Yuwen He, Guicheng Zhang, Pengjiu Yu, Guifa Zhong, Hongjiang Xu, Ling Yang, Shanchun Wang, Xin Zhao*, Wenhui Hu*. Rapid generation of a novel DPP-4 inhibitor with long-acting properties: SAR study and PK/PD evaluation. European Journal of Medicinal Chemistry, 2017, 141, 519-529.  

16. Yunlong Zhao, Qingxin Luo, Longsheng Wang, Wenhui Hu*, Junling Zhao*. Organocatalytic Friedel-Crafts Alkylation /Lactonization Reaction of Naphthols with 3-Trifluoroethylidene Oxindoles: The Asymmetric Synthesis of Dihydrocoumarins. Angewandte Chemie International Edition. 2017, 56, 338 –342.